GlassScriptPhysician profile
Vicki Y Lin
NPI 1326146937
$8,857.46
in general payments reported to CMS, 2019-2025
27 companies · $1,729 in 2025
The $1,729 reported for 2025 was more than what 87% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,694 · 2020: $521 · 2021: $1,000 · 2022: $1,605 · 2023: $659 · 2024: $650 · 2025: $1,729.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,019 · Education: $17.84.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,019.31 |
| Education | $17.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $2,132.59 | 2019-2025 | Clareon Panoptix Pro, Rocklatan, Tryptyr |
| Sun Pharmaceutical Industries INC. | $1,064.73 | 2019-2025 | Cequa |
| Abbvie INC. | $778.69 | 2022-2025 | |
| Oyster Point Pharma, INC. | $745.15 | 2022-2025 | Tyrvaya |
| Allergan, INC. | $654.50 | 2019-2022 | |
| Aerie Pharmaceuticals, INC. | $528.36 | 2019-2021 | |
| Bausch & Lomb Americas INC. | $342.39 | 2022-2025 | Miebo, Vyzulta, Prolensa |
| Dompe US, INC. | $335.75 | 2022-2025 | Oxervate |
| Shire North American Group INC | $279.58 | 2019 | |
| Ani Pharmaceuticals, INC. | $267.24 | 2024-2025 | Purified Cortrophin Gel |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $229.33 | 2019-2021 | |
| Sight Sciences, INC. | $197.29 | 2021-2022 | |
| Ivantis, INC | $174.26 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $169.10 | 2019-2023 | |
| Mallinckrodt Hospital Products INC. | $156.95 | 2025 | Acthar |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tarsus Pharmaceuticals, INC. | $146.65 | 2025 | Xdemvy |
| Thea Pharma INC. | $137.45 | 2023-2025 | Iyuzeh |
| New World Medical,INC. | $100.60 | 2022-2024 | Streamline, Clearpath, Ahmed Glaucoma Valve |
| Amgen INC. | $83.14 | 2025 | Tepezza |
| Harrow Eye, LLC | $82.15 | 2025 | Vevye |
| Eyevance Pharmaceuticals LLC | $72.48 | 2019-2022 | |
| Rayner Intraocular Lenses Limited | $54.10 | 2025 | Omidria |
| Alcon Research LLC | $34.59 | 2019 | |
| Rxsight INC | $26.98 | 2023 | Rxsight Light Delivery Device (Ldd), Rxsight Injector Handpiece, Rxsight Light Adjustable Lens (Rxlal) |
| Astellas Pharma US INC | $23.16 | 2019 | |
| Kala Pharmaceuticals, INC. | $20.85 | 2021 | |
| Carl Zeiss Meditec Ag | $19.40 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Vicki Lin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.